How Does Apremilast Work for Plaque Psoriasis?

Apremilast is an oral medication approved for plaque psoriasis that works by dialing down inflammation from the inside, without suppressing the immune system the way many other systemic treatments do. It earned FDA approval in 2014 and occupies a distinctive middle ground in the psoriasis treatment landscape: stronger than topical creams alone, less potent than injectable biologics, but far more convenient and with a lighter safety-monitoring burden. Its clinical track record across multiple large trials, along with some surprising effects on itch and quality of life, makes it worth understanding in detail.

How Apremilast Tamps Down Inflammation

Psoriasis is driven by an overactive immune response that sends inflammatory signals spiraling out of control, leading to the red, scaly plaques on the skin. Apremilast targets an enzyme called phosphodiesterase 4 (PDE4), which is the main enzyme responsible for breaking down a signaling molecule called cyclic AMP inside cells. When PDE4 is blocked, cyclic AMP levels rise, and that shift recalibrates the balance between pro-inflammatory and anti-inflammatory signals the cell produces.¹ In practical terms, apremilast reduces the output of several key inflammatory drivers, including tumor necrosis factor alpha (TNF-α) and interleukin-23, while boosting the anti-inflammatory cytokine IL-10.²

What makes this mechanism distinct from biologics is that apremilast modulates a broad network of mediators rather than blocking a single target. Biologics zero in on one cytokine or receptor with high precision, which is why they tend to produce stronger skin clearance. Apremilast’s broader but gentler approach means it does not carry the same immunosuppressive risks, but it also does not clear skin as dramatically. That trade-off is central to understanding where it fits.

Efficacy in Moderate-to-Severe Plaque Psoriasis

The landmark evidence for apremilast comes from the ESTEEM 1 and ESTEEM 2 trials, both large phase III studies in patients with moderate-to-severe plaque psoriasis. In ESTEEM 1, about a third of patients on apremilast achieved a 75% or greater improvement in their Psoriasis Area and Severity Index score (known as PASI 75) at week 16, compared with roughly 5% on placebo.³ ESTEEM 2 showed similar results, with about 29% of apremilast patients hitting PASI 75 versus roughly 6% on placebo, and about a fifth achieving clear or almost-clear skin by physician assessment.⁴

Those response rates are honest but modest. About one in three patients with moderate-to-severe disease gets a robust clearance response, which is far lower than what modern biologics achieve. But for patients who continued on apremilast through a full year, the numbers improved: in ESTEEM 1, about 61% of those who stayed on the drug through week 52 reached PASI 75.⁵ The takeaway is that apremilast works gradually and rewards patience, but it is not the right choice for someone who needs rapid, near-complete clearance.

Why Milder Psoriasis May Be Its Sweet Spot

Something that often gets overlooked is that apremilast was also studied specifically in mild-to-moderate plaque psoriasis, a population that historically falls into a frustrating gap: too much disease for topical creams to manage, but not severe enough for many dermatologists to consider jumping to a biologic. A phase III trial in this population found that about 22% of apremilast patients achieved clear or almost-clear skin at week 16, compared with 4% on placebo. Body surface area improvement, itch reduction, and scalp clearance all showed strong separation from placebo as well.⁶

A Japanese open-label study painted an even more favorable picture in milder disease, with about 44% of patients achieving clear or almost-clear skin by week 16.⁷ This is where apremilast may actually make the most clinical sense: in patients with mild-to-moderate disease who are struggling with topicals, it offers a meaningful step up without the monitoring burden and risks of heavier systemic therapies.

Nail and Scalp Psoriasis

Nail and scalp involvement are notoriously difficult to treat with topical therapies alone. Nails respond slowly to almost everything, and getting medication to the scalp through hair can be impractical. Data pooled from the ESTEEM trials showed that nail psoriasis improved steadily with apremilast over time: about 60% of patients saw at least a 50% improvement in their nail psoriasis score by week 52.⁸ Scalp responses came faster. In ESTEEM 1, about 73% of patients achieved clear or almost-clear scalp by week 52, and ESTEEM 2 showed a similar trajectory.⁹

For patients whose biggest complaint is crumbling nails or a flaky, itchy scalp, these numbers are worth noting. Nail improvement takes months to become visible regardless of the treatment, so apremilast’s gradual mechanism may actually be a natural fit for a body site that requires patience anyway.

Joint Disease and Psoriatic Arthritis

Psoriasis is not just a skin disease. Up to a third of people with psoriasis develop psoriatic arthritis, a painful inflammatory condition affecting joints and tendons. Apremilast is approved for psoriatic arthritis as well, based on the PALACE trial program. In the PALACE 3 trial, which enrolled patients with both active joint disease and skin involvement, about 41% of patients on the 30 mg dose achieved at least a 20% improvement in joint symptoms at week 16, compared with 18% on placebo. Among those with significant skin involvement, roughly 41% also reached a 50% improvement in their skin scores.¹⁰ These improvements held through a full year with continued treatment.

The joint response rates are moderate compared to biologic therapies, but for patients with mild-to-moderate joint symptoms who want to avoid injections, apremilast offers a practical oral option that addresses both skin and joints simultaneously.¹¹

Itch Relief Comes Early

One of apremilast’s underappreciated strengths is how quickly it tackles itch, which is often the symptom that bothers patients most. In the ESTEEM trials, significant improvements in itch appeared as early as week 2, well before visible skin clearance was evident. Reductions in itch scores correlated strongly with improvements in quality-of-life measures, which makes intuitive sense: if you are no longer lying awake scratching, your life improves even before your skin looks dramatically different.¹²

Phase IIb data showed that patients on the 30 mg dose experienced about a 44% improvement in itch scores from baseline, compared with roughly a 6% improvement on placebo.¹³ Standard psoriasis scoring tools like PASI focus on visible redness, thickness, and scaling, and they do not capture itch at all. So the clinical trial headline numbers for apremilast sometimes understate its effect on the symptom patients care about most.

Side Effects and Safety Profile

The most common side effects during the first year of treatment were gastrointestinal: diarrhea, nausea, and, less often, abdominal discomfort. Upper respiratory tract infections, headache, and tension headache also occurred in more than 5% of patients. Importantly, no new side effects emerged after the first year in pooled long-term safety data spanning three years or more.¹⁴

The GI side effects tend to be worst in the first two weeks and usually settle down. The standard titration schedule, which starts at a low dose and ramps up over five days, is specifically designed to reduce this early GI discomfort. Still, for some people the diarrhea or nausea proves persistent enough to drive them off the drug.

A more serious concern involves mood. Real-world pharmacovigilance data from the FDA’s adverse event reporting system flagged depression, suicidal ideation, and insomnia as potential signals beyond the well-known GI effects.¹⁵ The drug’s prescribing label already warns about this. People with a history of depression or suicidal thoughts should discuss it with their prescriber before starting, and anyone who notices new or worsening mood symptoms while on the drug should flag it immediately.

One practical advantage that often tips the scales toward apremilast is the lack of routine laboratory monitoring. Unlike methotrexate, which requires regular blood draws to check liver function and blood counts, apremilast does not carry organ-toxicity risks that demand ongoing bloodwork. For patients who dislike needles or who have limited access to regular lab testing, that convenience factor is real.

How It Stacks Up Against Other Treatments

In head-to-head comparisons with methotrexate, one of the oldest systemic psoriasis treatments, apremilast performed comparably or slightly better. One randomized trial in chronic plaque psoriasis found a statistically greater median improvement in psoriasis scores with apremilast than with methotrexate.¹⁶ In palmoplantar psoriasis, a particularly stubborn subtype affecting the palms and soles, the two drugs showed comparable efficacy and safety.¹⁷

The comparison with biologics is less flattering. A large network meta-analysis ranking all major psoriasis therapies found that apremilast’s short-term rate of achieving a 90% skin-clearance response was about 12%, while top-performing biologics like ixekizumab and risankizumab hovered above 70%.¹⁸ That is a stark gap, and it is the main reason most dermatologists reserve apremilast for patients who either have milder disease, cannot take or prefer to avoid biologics, or need a bridge therapy while making a treatment decision.

Cost matters here too. A German real-world database study found that adjusted drug costs over the follow-up period were thousands of euros lower for apremilast than for biologics targeting IL-17, IL-23, or TNF-α.¹⁹ In cost-effectiveness modeling, apremilast consistently emerges as one of the most cost-effective first-line targeted therapies.²⁰

How Long People Actually Stay On It

Clinical trial results show what happens under ideal conditions: patients enrolled in a study with regular check-ins and support. Real-world persistence tells you something different. A registry analysis found that about 57% of psoriasis patients were still on apremilast after 12 months.²¹ Younger patients (under 40) were significantly more likely to stop, while other factors like sex, obesity, and whether the patient had previously tried a biologic did not affect persistence.

A large French database study comparing apremilast to methotrexate found an even steeper drop-off: about 69% of apremilast patients discontinued in the first year versus 59% for methotrexate, and apremilast had a roughly 34% higher hazard of discontinuation when matched head-to-head.²² For psoriatic arthritis, the picture is even bleaker: one study found a median persistence of only about six months, with under 17% of patients still on treatment at study’s end.²³

These numbers are sobering and worth knowing if you are considering apremilast. High discontinuation rates typically reflect a mix of inadequate efficacy and GI side effects. In practice, many dermatologists frame apremilast as a drug that works well for the people it works for, and the first 12 to 16 weeks serve as a trial period. If you are seeing clear benefit and tolerating the drug by then, you are likely to be a long-term responder.

Combining Apremilast With Other Treatments

Because apremilast works through a different pathway than most other psoriasis therapies, it is a reasonable candidate for combination use. A review of 15 studies examining apremilast combined with topicals, phototherapy, or other systemic agents found generally favorable safety and efficacy across the board.²⁴

The combination with phototherapy (UV light treatment) has specific data. In one controlled study, patients who received apremilast plus phototherapy had more side effects than those receiving phototherapy alone — mostly the expected GI complaints plus soft stools and headache — but no unexpected safety concerns emerged.²⁵ For patients whose skin is partially responding to apremilast, adding targeted phototherapy sessions is a common strategy clinicians use to push toward better clearance without switching to a biologic.

Pediatric Use

Treating children with psoriasis presents a specific challenge: parents and clinicians are understandably cautious about long-term immunosuppression, and the list of approved systemic options for pediatric patients is short. Apremilast has been studied in children and adolescents through the SPROUT trial. At week 16, significantly more children on apremilast achieved clear or almost-clear skin and PASI 75 responses than those on placebo, regardless of age, weight, or baseline severity.²⁶

Through 52 weeks, about half the population reached those benchmarks, and the dropout rate was low, with over 84% of patients who entered the extension phase completing the study. The safety profile in children was consistent with what is seen in adults, with no new safety signals.²⁷ Dosing in children is weight-based and calibrated to produce drug exposure similar to the standard adult dose.²⁸ GI side effects were somewhat more frequent in children than in adult studies, with nausea and headache reported by roughly half of pediatric participants, though these mostly resolved within a few days.

Kidney Impairment and Dose Adjustments

Apremilast is cleared through the kidneys, which matters for people with reduced kidney function. A dedicated pharmacokinetic study found that patients with severe kidney impairment had nearly double the drug exposure compared to healthy controls, along with slower elimination. For mild or moderate kidney impairment, no dose change is needed. For severe impairment, the dose is reduced from the standard 30 mg twice daily to 30 mg once daily.²⁹ This is straightforward compared to some biologics, where dosing adjustments for organ impairment are either poorly studied or more complicated.

Effects Beyond the Skin

Psoriasis is increasingly recognized as a systemic inflammatory disease with effects extending beyond the skin, including elevated cardiovascular risk. Researchers tested whether apremilast could reduce vascular inflammation, measured by imaging of the aorta, in psoriasis patients. The study found no significant change in aortic inflammation at either 16 or 52 weeks. However, some potentially favorable metabolic shifts did emerge: reductions in certain inflammatory markers and branched-chain amino acids at week 16, and decreases in ferritin and ketone bodies by week 52. There was also an approximately 5-6% reduction in both subcutaneous and visceral fat that persisted through a year.³⁰

The modest weight loss is something patients sometimes notice and clinicians find intriguing, since psoriasis and obesity frequently coexist and worsen each other. Whether these metabolic improvements translate into actual cardiovascular event reduction remains unknown, but they add an interesting dimension to the drug’s profile that extends beyond skin clearance scores. Some biologics targeting IL-17 or IL-23 have shown stronger vascular anti-inflammatory effects, so apremilast is not the strongest choice if cardiovascular risk reduction is a primary treatment goal.